The challenge of post-implementation surveillance for novel meningococcal vaccines.
Novel serogroup B meningococcal vaccines are currently in late stage development and may be used in mass immunisation campaigns over the coming years. This represents an exciting development in the prevention of childhood meningitis, however monitoring the impact of these vaccines on meningococcal disease epidemiology will provide significant challenges. Although designed to prevent serogroup B meningococcal disease the vaccine antigens are not serogroup specific, creating the potential for multiple definitions of vaccine effectiveness and vaccine failure.
Oxford Universities Hospitals NHS Trust, United Kingdom. matthew.snape@paediatrics.ox.ac.uk
Matthew D
MD
Snape
Duccio
D
Medini
Scott A
SA
Halperin
Lisa
L
DeTora
Jonathan
J
Drori
E Richard
ER
Moxon
D006801:Humans; D008589:Meningococcal Infections / Q000453:epidemiology* / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D038541:Neisseria meningitidis, Serogroup B / Q000302:isolation & purification*; D011358:Product Surveillance, Postmarketing / Q000379:methods; D018571:Sentinel Surveillance
D022401:Meningococcal Vaccines